抗KIR2DL1/KIR2DS5抗体(Anti-Human KIR2DL1/CD158a Allophycocyanin antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Allophycocyanin
Immunogen	BaF3 mouse pro-B cell line transfected with human KIR2DL1/KIR2DS5 Accession # P43626
Source	Monoclonal Mouse IgG1 Clone # 143211
Purification	Protein A or G purified from hybridoma culture supernatant
Specificity	Detects human KIR2DL1/KIR2DS5 on transfected cells. It does not stain cells transfected with KIR2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS4, 3DL1, 3DL2, or 3DS1.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Flow Cytometry	10 µL/106 cells	See below

Flow Cytometry

Detection of KIR2DL1/KIR2DS5 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) were stained with Mouse Anti-Human KIR2DL1/KIR2DS5 APC‑conjugated Monoclonal Antibody (Catalog # FAB1844A) and Mouse Anti-Human NCAM‑1/CD56 PE‑conjugated Monoclonal Antibody (Catalog # FAB2408P). Quadrant markers were set based on control antibody staining (Catalog # IC002A). View our protocol for Staining Membrane-associated Proteins.

目次に戻る

Related Product & Information

Background	KIR2DL1/KIR2DS5
background_content	Background: KIR2DL1/KIR2DS5 KIR2DL1 is one of several immunoglobulin-like receptors expressed on NK cells that bind MHC class I molecules and transmit inhibitory signals. KIR2DL1 is specific for HLA-C alleles with Asn77 and Lys80.

目次に戻る

Citations

1. NK Cell Responses to Human Tick-Borne Encephalitis Virus Infection
   J Immunol, 2016;0(0):.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


2. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells.
   Authors: Marquardt N, Beziat V, Nystrom S, Hengst J, Ivarsson M, Kekalainen E, Johansson H, Mjosberg J, Westgren M, Lankisch T, Wedemeyer H, Ellis E, Ljunggren H, Michaelsson J, Bjorkstrom N
   J Immunol, 2015;194(6):2467-71.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


3. Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation.
   Authors: Killig M, Friedrichs B, Meisig J, Gentilini C, Bluthgen N, Loddenkemper C, Labopin M, Basara N, Pfrepper C, Niederwieser D, Uharek L, Romagnani C
   Eur J Immunol, 2014;44(9):2822-34.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


4. Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection.
   Authors: Charoudeh H, Terszowski G, Czaja K, Gonzalez A, Schmitter K, Stern M
   Eur J Immunol, 2013;43(2):480-7.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


5. CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients.
   Authors: Beziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, Hervier B, Theodorou I, Martinot M, Debre P, Bjorkstrom NK, Malmberg KJ, Marcellin P, Vieillard V
   Eur. J. Immunol., 2012;42(2):447-57.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


6. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.
   Authors: Beziat V, Descours B, Parizot C, Debre P, Vieillard V
   PLoS ONE, 2010;5(8):e11966.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


7. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.
   Authors: Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS
   Blood, 2008;111(6):3155-62.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow

目次に戻る